September 17, 2019 7:00pm

Wednesday could be an implicating day; the Fed is expected to cut the benchmark rate by one quarter of a percentage point to a range of 1.75% to 2%

Could it push “our” universe back into a safe haven and “some” upside to the oversold?

Reiterating, the need for positive clinical read-outs

As the leading voice of cell and gene therapy investors; I am not always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and operating roles) with the gray hair and a readership g with extrapolations to prove it!


 

There are a variety of end uses to sector forecasts; the most prominent, they are used to protect your portfolio’s life and value.

 

Markets and indexes:

  • The Dow closed 33.98 points or +0.13% to 27,110.80;
  • The S&P closed up +7.74 points or +0.26% at 3,005.70;
  • The NASDAQ was up +32.47 or +0.40% to 8,186.02;

 

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Tuesday the IBB closed up +0.05% while the XBI also closed down -0.29%
  • Monday the IBB closed up +0.94% while the XBI also closed up +1.44%
  • Friday the IBB closed up +0.05% while the XBI also closed down -0.23%

 

Henry’omics:

Our “universe” fell into a rut in the sector while indexes rose slightly on Tuesday, but gains were capped as the Federal Reserve kicked off a two-day monetary policy meeting.

The major indexes were within striking distance of their record highs. The Dow and S&P 500 were about 1% below all-time highs set in July while the NASDAQ was 2.1% below its record mark.

 

There is just NO correlation between volatility and expectation

The drama is reflected by resistance and the loss of positive sentiment as September and Q3 slowly evolves to its end!

 

The advance/decline line scenario of 45 covered companies:  

  • Tuesday the close was positive with an Advance/Decline (A/D) line of 14/27 and 2 flat and 2 acquired;
  • Monday the close was positive with an A/D line of 31/11 and 1 flat and 2 acquired;
  • Friday the close was negative with an A/D Line of 18/22 and 3 flats and 2 acquired;

 

Decliners:

  • Ionis Pharmaceuticals (IONS -$1.07 after Friday’s -$0.68 after Thursday’s +$2.05, Wednesday’s +$2.04, Tuesday’s+$2.67 and last Monday’s -$1.63);
  • Global Blood Therapeutics (GBT -$0.90);
  • uniQure (QURE -$0.57 after Friday’s -$1.08);
  • AxoGen (AXGN -$0.39);
  • Caladrius Biosciences (CLBS -$0.13);

Incliners:

  • ReNeuron (RENE.L +$10.00);
  • Sage Therapeutics (SAGE +$5.56 after Friday’s -$1.11);
  • Regenxbio (RGNX +$2.01 after Friday’s -$1.64 and Thursday’s +$2.18);
  • bluebird bio (BLUE +$2.01 after Friday’s +$1.74, Thursday’s +$2.03, Wednesday’s-$0.71 and last Tuesday’s +$2.14);
  • CRISPER Therapeutics (CRSP +$2.00);

 

The percentage (%) indicators: 

  • Tuesday’s range of the 14 upside was +0.04% (EDIT) to +17.09% (CLBS) while the 27 downside ranged from -0.13% (BLUE) to -7.02% (XON);
  • Monday’s range of the 32 upside was +0.03% (ONCE) to +8.82% (ADVM) while the 11 downside ranged from -0.23% (PSTI) to -5.26% (CLBS);
  • Friday’s range of the 18 upside was +0.40% (CLBS) to +8.25% (HSGX +$0.017) while the 22 downside ranged from -0.21% (BMRN) to -5.41% (ONVO);

 

Upside volume stats:  to compare

  • Tuesday: 3 out of the 14 upside had higher than the 3 month average volume;
  • Monday: 6 out of the 32 upside had higher than the 3 month average volume;
  • Friday: 5 out of the 18 upside had higher than the 3 month average volume;

Downside volume stats:

  • Tuesday: 9 out of the 27 downside had higher than the 3 month average volume;
  • Monday: 3 out of the 11 downside had higher than the 3 month average volume;
  • Friday: 6 out of the 22 downside had higher than the 3 month average volume;

 

2 flat – MDXG and RENE.L with 2 acquired (AST & OSIR) and Spark Therapeutics’ (ONCE) acquisition by Roche still being delayed (SEPTEMBER?)

 

September’s sessions:

Tuesday closed NEGATIVE with 27 decliners, 14 advancers, 2 flat and 2 acquired (AST & OSIR);

Monday closed POSITIVE with 11 decliners, 32 advancers, 0 flat and 2 acquired (AST & OSIR);

Friday closed NEGATIVE with 22 decliners, 18 advancers, 3 flats and 2 acquired (AST & OSIR);

Thursday closed NEGATIVE with 26 decliners, 17 advancers, 0 flats and 2 acquired (AST & OSIR);

Wednesday closed POSITIVE with 15 decliners, 26 advancers, 2 flats and 2 acquired (AST & OSIR);

Tuesday closed POSITIVE with 10 decliners, 31 advancers, 2 flats and 2 acquired (AST & OSIR);

Monday closed POSITIVE with 18 decliners, 25 advancers, 0 flat and 2 acquired (AST & OSIR);

Friday closed NEGATIVE with 26 decliners, 16 advancers, 1 flat and 2 acquired (AST & OSIR);

Thursday closed POSITIVE with 11 decliners, 31 advancers, 1 flat and 2 acquired (AST & OSIR);

Wednesday closed POSITIVE with 20 decliners, 22 advancers, 1 flat and 2 acquired (AST & OSIR);

Tuesday closed NEGATIVE with 29 decliners, 12 advancers, 2 flats and 2 acquired (AST & OSIR);

Monday was Labor Day

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.